Parkinson s Disease and Treatment Options for the Younger Adult
|
|
- Victor Dorsey
- 6 years ago
- Views:
Transcription
1 Parkinson s Disease and Treatment Options for the Younger Adult David E. Riley, M.D. Chair, Medical Education InMotion April 22, 2016 Case Presentation - 1 A 57-year-old woman had Tremor of her right hand off and on for 3 months Tremor mainly while reading or watching television Handwriting has become small Trouble beating an egg with her right hand Her family had noted A loss of facial expression She doesn t swing her right arm when she walks Case Presentation - 2 On exam, she showed Reduced blinking and facial expression Soft, monotonous voice General lack of movement Activated rigidity in the right upper limb Slowness of repetitive movements with the right hand Tremor of the right hand when she walks
2 James Parkinson s monograph Core clinical features: Tremor Rigidity Akinesia Postural disturbances Tremor Rest tremor (characteristic) Occurs in repose 3-7 Hz (slow) TIP: Watch for rest tremor while walking, or during tasks of concentration (e.g., arithmetic, reciting months backward) Action tremor (less common) Occurs with muscle activation 6-11 Hz (fast) Rigidity Muscle tone: Increased passive resistance A sign clinicians elicit, not a symptom Unlike spasticity, uniform in antagonists, throughout a joint range, regardless of speed TIP: Accentuated by contralateral activity Cogwheeling : correlated with tremor, not rigidity
3 Akinesia Akinesia : from the Greek for lack of movement Impairment of voluntary movement Typically causes most of the disability in PD Akinesia 3 components: Bradykinesia (decreased speed of movement) e.g. Slow initiation and execution of all movement Hypokinesia (decreased amplitude of movement) e.g. Micrographia, decreased arm swing, short stride Oligokinesia (decreased quantity of movement) e.g. Reduced blink and facial expression TIP: Tendency to progressive fatigue with repetition Micrographia
4 Postural Disturbances Flexion posture Disorder of equilibrium Exam: Test for retropulsion Pull backward on shoulders Normal: recover balance in 2 steps Parkinsonism vs. Parkinson s Parkinsonism a syndrome consisting of Tremor Rigidity Akinesia Postural disturbances Parkinsonism vs. Parkinson s Parkinson s Disease A degenerative disease with characteristic motor and non-motor clinical features, epidemiology, evolution, prognosis, treatment and pathology Parkinson s disease is the most common cause of parkinsonism, but not the only cause
5 Non-Motor Features Cognitive (dementia, excess somnolence) Autonomic (constipation, orthostatic hypotension, incontinence, sexual or sweat dysfunction) Sensory (restless legs, loss of smell) Miscellaneous (depression, REM-sleep behavior disorder) Premotor Features May precede motor onset by decades Strongest evidence established for: Olfactory deficit Constipation REM-sleep behavior disorder Excess daytime somnolence Depression, anxiety Savica et al. Arch Neurol 2010; 67: Lang. Mov Disord 2011; A Redefinition of PD Preclinical PD Pathology present; no clinical findings Premotor PD Early non-motor symptoms and signs Motor PD Classic motor manifestations Stern M, et al. Mov Disord 2012; 27: 54-60
6 Epidemiology Affects approximately 1 million patients in USA Prevalence: 0.3% of general population 1-3% of those older than 65 years Average age of onset is 60 years most notice first symptoms in their 50s or 60s ~5% of PD patients develop first symptoms before age 40, ~15% before age 50 ( young-onset PD, or YOPD) Typical Clinical Course Starts in one limb Dominant:non-dominant = 3:2 Progresses slowly over months and years Typically first to the other limb on the same side Eventually becomes bilateral, but remains worse on the side first affected Tremor, rigidity and akinesia early; postural instability late Etiology Multiple gene mutations now associated with PD Genetic factors play a larger role in patients with young-onset PD Environmental insults probably play a role in patients with PD onset after age 50 Excessive protein ( -synuclein) accumulation is found in all cases of PD
7 How is PD different for younger adults? Definition of young-onset PD Usually defined as onset < 40 or < 50 years But definitions vary widely Here I use < 50 years old, unless stated Etiology: More frequent (+) family history Onset < 50: risk of PD in sibs Sibs at risk of also developing PD < 50 y.o. Barrett et al. Mov Disord 2015; 30: How is PD different for younger adults? Delayed diagnosis of PD with onset < 45 y.o. Mean 15 additional months until diagnosis in PD patients Higher number of visits to neurologists prior to dx Higher number of lab investigations prior to dx Rana et al. J Neurol Sci 2012; 323: Usually need care beyond initial doctor s career How is PD different for younger adults? Course: Progression is slower Mortality Life expectancy (LE) closer to normal in relative, but not absolute, terms e.g., onset age 25-39: lose 22% LE, or 11 years; onset age > 64: lose 44% LE, or 4 years Wickremaratchi et al. Eur J Neurol 2009; 16: 450 6
8 How is PD different for younger adults? Increased rates of: onset with non-tremor symptom dystonia (at onset or during treatment) levodopa-induced dyskinesias depression, anxiety Clinical manifestations and complications: Lower rates of early gait difficulty falls, freezing dementia autonomic disturbances Mehanna et al. Park Rel Dis 2014; 20: Pagano et al. Neurology 2016; 86: 1 8 Wickremaratchi et al. Eur J Neurol 2009; 16: How is PD different for younger adults? Psychosocial effects more likely to become unemployed or retire early negative effects on finances, role functioning, social contacts, self-esteem experience more family and marital problems have higher depression scores rate their quality of life as worse than do patients with older onset with similar disease severity may need more support of family members Schrag A, et al. Mov Disord 2003; 18: Schrag A, Schott J. Lancet Neurol 2006; 5: Pathology Gross: Pallor of substantia nigra Microscopic: Loss of > 50% of substantia nigra neurons In surviving neurons, cytoplasmic inclusions called Lewy bodies Lewy bodies contain α-synuclein Loss of substantia nigra neurons results in loss of dopamine in nigrostriatal tract
9 Lewy Body A Chemical Balancing Act In the basal ganglia, dopamine is in dynamic equilibrium with acetylcholine Dopamine Acetylcholine Antiparkinsonian drugs either compensate for missing dopamine, or antagonize acetylcholine Currently Available Medications Anticholinergics Amantadine Carbidopa/Levodopa Dopamine agonists MAO (monoamine oxidase) inhibitors COMT (catechol-o-methyl transferase) inhibitors
10 Anticholinergic Drugs Trihexyphenidyl (Artane ) preferred by movement disorder specialists due to lower rate of sedation Benztropine (Cogentin ) Diphenhydramine (Benadryl ) all available as generics Anticholinergic Drugs Good for relief of tremor, little else The most notorious for causing cognitive side effects (memory loss, psychosis, confusion) Poorly tolerated by elderly patients Also cause dry mouth, blurred vision, other antimuscarinic effects Main indication: for young patients (< 60 years) whose predominant symptom is resting tremor Amantadine Antiviral drug with uncertain mechanism of antiparkinsonian effect Hubsher G, et al. Neurology 2012; 78: Modest benefit for all symptoms Second worst for causing cognitive effects Other adverse effects: Dry mouth Livedo reticularis Pedal edema
11 Case Presentation - 3 Our patient initially declined any symptomatic treatment After 6 months, she reported an increase in slowness with activities of daily living A trial of amantadine 100 mg b.i.d. produced satisfactory improvement Case Presentation - 4 Our patient reported increased symptoms 6 months later These responded to an increase in amantadine to 100 mg t.i.d. However, she soon developed swelling of her legs associated with a mottled appearance of her skin Amantadine was discontinued Amantadine One option for patients with mild symptoms May have more prolonged benefit than generally acknowledged Effective symptomatic treatment for levodopa-induced dyskinesias
12 Levodopa Marketed in U.S.A. in combination with carbidopa as Sinemet to reduce nausea Carbidopa has no anti-pd effect; pure antinauseant 1975: Sinemet = sine + emesis Initially formulated in carbidopa/levodopa ratio of 1:10 Now the standard ratio is 1:4 Current U.S.A. Formulations Sinemet (carbidopa/levodopa tablets) ratios: 10/100, 25/100, 25/250 Sinemet CR (controlled-release carbidopa/levodopa tablets) ratios: 25/100, 50/200 Parcopa (orally disintegrating carbidopa/levodopa tablets) ratios: 10/100, 25/100, 25/250 Stalevo (carbidopa/levodopa tablets plus entacapone): 12.5/50/200, 18.75/75/200, 25/100/200, 31.25/125/200, 37.5/150/200, 50/200/200 Rytary (capsules contain both immediate-release and extended-release beads of carbidopa-levodopa): 23.75/95, 36.25/145, 48.75/195, 61.25/245 Duopa (enteral suspension of carbidopa-levodopa): 4.63/20 per ml (in cartridges of 100 ml) Benefits of Levodopa The most effective drug in the treatment of motor manifestations of PD the cornerstone of treatment of PD for >40 years Virtually all (94%) patients with confirmed PD experience clinically significant benefit Associated with reduced disability compared to the pre-levodopa era Possibly associated with decreased mortality compared to the pre-levodopa era
13 Micrographia response to levodopa : Sinemet 25/100 two tablets t.i.d. Limitations of Levodopa Only one common early side effect: nausea Two problems with levodopa as PD progresses: 1. Fluctuations in symptom severity due to premature wearing off of benefit prior to the next dose 2. Involuntary movements (dyskinesias) Both fluctuations and dyskinesias are more common in younger patients Dopamine Agonists Act by direct stimulation of the postsynaptic dopamine receptors Molecular structure similar to dopamine Effective against most principal PD manifestations Tremor Akinesia Rigidity
14 Dopamine Agonists Currently available in the U.S.A.: Pramipexole (Mirapex ): 3 times a day extended-release (Mirapex ER ): once daily Ropinirole (Requip ): 3 times a day extra-long-acting (Requip XL ): pill once daily Apomorphine (Apokyn ): injectable as needed Rotigotine (Neupro ): skin patch once daily Micrographia response to medication January 2009 Prior to treatment August 2010 Ropinirole XL 8 mg daily Levodopa vs. Dopamine Agonists Side Effects Levodopa Nausea Dyskinesias Fluctuations Dopamine agonists Hallucinations/ psychosis Sedation Impulse-control disorders Edema Orthostatic hypotension
15 Dopamine Agonists Two main concerns with long-term dopamine agonist therapy: Sudden sleep attacks, concern with driving Impulse-control disorders Gambling Compulsive buying Hypersexuality, promiscuity Binge eating 17.1% on DA agonists vs. 6.9% not taking; OR 2.7 Weintraub et al. Arch Neurol 2010; 67: COMT & MAO-B Inhibitors Catechol-O-methyl transferase and Monoamine oxidase B enzymes break down dopamine Inhibitors of these enzymes allow dopamine molecules to survive longer Useful in patients with PD experiencing end-ofdose wearing off with levodopa Side effects similar to increasing levodopa MAO-B Inhibitors Selegiline (Eldepryl ) One size: 5 mg, max 5 mg b.i.d.; generic available Very modest symptomatic benefit Initially thought that selegiline slows progression in PD, but later disproved Orally dissolving selegiline (Zelapar ) 1.25 mg Rasagiline (Azilect ) 0.5 mg or 1 mg; once-a-day dosing, generic not available yet Many times more potent than selegiline Effective treatment for motor fluctuations Also approved for solo use
16 COMT Inhibitors Tolcapone (Tasmar ) Three doses daily More potent than entacapone Requires liver function monitoring Entacapone (Comtan ) 200 mg taken with each dose of levodopa Less effective than tolcapone No laboratory surveillance required Available in combination with carbidopa/levodopa (Stalevo ) Initial Pharmacologic Treatment - Mainstream Approach - Use anticholinergics, amantadine or rasagiline for milder symptoms Use levodopa or dopamine agonists when disability occurs Under 60 years old Maximize use of non-dopaminergic drugs Use dopamine agonists before levodopa Over 70 years old, prefer levodopa Long-Term Pharmacologic Treatment Principles Use minimum dose that provides satisfactory benefit TIP: In general, use small doses of multiple drugs, rather than large doses of any single drug Polypharmacy has become the norm in PD Lack of drug interactions permits this At each visit, be attentive to: Possible side effects Gaps of time in symptom relief Non-motor complications
17 Case Presentation - 5 Off amantadine, our patient felt severely impaired, and her tremor was more prominent than ever Due to her age (still under 60), she began pramipexole At a dose of pramipexole 1 mg t.i.d., she did well for 2 years After 2 years, she required the addition of Sinemet She said she had trouble tolerating Sinemet initially, especially the morning dose A pharmacy brochure had instructed her to take it on an empty stomach, and she became violently ill Management of PD Complications in Younger Adults Motor Fluctuations 1. Shorten levodopa dose interval, or increase dose quantity 2. Extended-release levodopa preparations 3. Protein redistribution diet 4. Increase/add dopamine agonist 5. Add COMT inhibitor; MAO-B inhibitor 6. Amantadine 7. Surgical approaches Management of PD Complications in Younger Adults Peak-Dose Dyskinesias 1. Reduce levodopa dose 2. Reduce or eliminate levodopa boosters MAO and COMT inhibitors 3. Substitute for levodopa with other antiparkinsonian medications 4. Trial of amantadine 5. DBS Surgery
18 Deep Brain Stimulation (DBS) Current surgical procedure of choice for PD Reduces patients dependence on medication Provides more consistent symptom control Does not produce benefit beyond the best results from medication, except for tremor Deep Brain Stimulation (DBS) Current surgical procedure of choice for PD Reduces patients dependence on medication Provides more consistent symptom control Does not produce benefit beyond the best results from medication, except for tremor Patients most likely to benefit from DBS: Young Tolerate surgery better, longer benefit Suffering from dyskinesias and fluctuations Tremor unresponsive to medication Duopa Surgical Enhancement of Medication Delivery Carbidopa/levodopa enteral suspension Administered directly into the small intestine via PEG- J (percutaneous endoscopic gastrostomy with jejunal extension) Pump provides continuous levodopa supply for 16 hours At night, pump disconnected and patients take oral meds Indicated for treatment of motor fluctuations
19 Other Treatment Options Hypophonia Lee Silverman Voice Therapy Balance Physical therapy specialists Common PD Management Issue Sudden Deterioration! In parkinsonism (motor function) or In cognitive function (confusion, hallucinations) Parkinson s disease is slowly progressive Sudden deterioration indicates a superimposed condition Most likely: urinary tract infection, often asymptomatic Also: other infections, new medications Parkinson s Disease in General Medicine
20 Prediagnostic PD in Primary Care Prediagnostic presentations of Parkinson s disease in primary care: a case-control study Schrag A, et al. Lancet Neurol 2014; 14: Retrospective database review of 8,166 with PD vs. 46,755 non-pd 5 years prior to dx, higher incidence in future PD patients of: tremor, balance impairments, constipation, hypotension, erectile dysfunction, urinary dysfunction, dizziness, fatigue, depression, and anxiety 10 years prior to dx, higher incidence in future PD patients of: tremor, constipation Autonomic Dysfunction Cardiovascular dysfunction Gastrointestinal dysfunction Genitourinary dysfunction Sweating dysfunction Autonomic - Cardiovascular Blood pressure instability Wide swings in BP throughout the day often spiking over 200 systolic BP fluctuation > 100 mmhg observed in 64.9% of PD patients (by ambulatory monitoring) Tsukamoto et al. Brain and Behavior 2013; 3: Nighttime hypertension Long-term trend toward low BP Mandates to control high BP cause physicians to treat minor cases leading to more frequent bouts of low BP
21 Autonomic - Cardiovascular As PD progresses, watch for: Resolution of prior hypertension Orthostatic hypotension Drugs for PD, esp. dopamine agonists, can aggravate the tendency to low BP Postprandial hypotension Syncope BP Target Recommendation The risks of supine hypertension in this setting are largely statistical and long-term, whereas those of orthostatic hypotension are real and immediate. Therefore, at our centre, we set a goal of a systolic blood pressure while standing of at least 100 mm Hg, in the morning. Goldstein D. Compr Physiol 2014; 4: Autonomic - Gastrointestinal - Constipation - The most common autonomic complication of PD Increased colonic transit time may worsen with disease progression Contributing factors Physical inactivity Delayed stomach transit Diminished fluid intake Some antiparkinsonian medications
22 Autonomic - Genitourinary Bladder Storage failure Urinary urgency Urinary frequency Urinary incontinence Bladder Voiding failure Urinary retention, may lead to infection Impotence Medical Comorbidities of PD Bone metabolism and joint diseases Osteoporosis 25-hydroxy-vitamin D3 deficiency Fractures Especially increased risk of hip/femoral fracture Frozen shoulder Low back pain Spinal deformity (camptocormia, Pisa syndrome) Poorer outcomes from shoulder and hip surgery Medical Comorbidities of PD Cancer Overall lower incidence of, and mortality from, cancer in PD Strong association: melanoma Higher risk in both patients and relatives Also increased risk: prostate, thyroid Reduced risk: colorectal, lung, pancreas, stomach
23 Medical Comorbidities of PD Other comorbidities Traumatic injuries other than fractures Deep vein thrombosis Associated with wheelchair use and postural abnormalities Malnutrition Medical Side Effects of PD Medications Orthostatic hypotension: dopamine agonists Peripheral edema: dopamine agonists, amantadine Nausea: levodopa Diarrhea: COMT inhibitors Constipation: anticholinergics Urinary retention: anticholinergics Common Errors in PD Management Levodopa Formulations A patient started Sinemet 25/100 and developed nausea. He was switched to the lower dose of Sinemet 10/100. The second number in carbidopa/levodopa formulations lists the mg content of the active ingredient (levodopa); the first is carbidopa Carbidopa is added to levodopa only to reduce nausea Thus switching a patient from 25/100 to 10/100 does not represent a lower dose of antiparkinsonian medication Paradoxically, patients suffer more side effects from 10/100 tablets than 25/100 tablets
24 Common Errors in PD Management Instigation of Nausea A patient started Sinemet 25/100. She followed the pharmacy directive not to take the medication with food. She developed nausea. Pharmacies often take a one-size-fits-all approach to PD Interference from protein is only a significant consideration in patients with dose-related fluctuations Instruct patients to ignore any pharmacy directive that contradicts your recommendation to take Sinemet with food at the beginning Common Errors in PD Management Treatment of Nausea A patient started Sinemet 25/100 and developed nausea. He was prescribed metoclopramide (Reglan ). Metoclopramide, prochlorperazine (Compazine ) and other antinauseants are dopamine receptor blockers. They aggravate PD. 4 remedies for nausea caused by levodopa Initiate carbidopa/levodopa after meals Take extra carbidopa 25 mg tablets Ondansetron (Zofran ); inactive at dopamine receptors Definitive Rx: domperidone (not dispensed in U.S.A.) Common Errors in PD Management Treatment of Hallucinations A patient began seeing people in the house who were not there. A physician prescribed risperidone. Risperidone, haloperidol, and most other antipsychotics are dopamine receptor blockers. They aggravate PD. Consider the following sequence of interventions Look for evidence of occult infection, especially UTI Withdraw anticholinergics, then amantadine, then dopamine agonists Prescribe a cholinesterase inhibitor (rivastigmine, donepezil)* Consider quetiapine or clozapine for an antipsychotic *Off-label
25 Lifestyle Intervention Physical Activity Physical activity: all forms are beneficial for PD patients Exercise Traditional, especially stretching Tai chi, yoga Dance (tango, ballroom, Irish set dancing, etc.) Sports (cycling, boxing, kayaking) Patients should be told: Exercise/activity is as important for PD as taking meds So find something they are willing to do regularly, and do it! Exercise, dance, sports, voice classes 5 days/week All led by certified instructors Support groups for patient and partners Bimonthly lectures by physicians and other professionals And much more all free of charge! Check us out at beinmotion.org Conveniently located near I-480 and I-271
26 Recommended Reading Calne S, Kumar A. Young onset Parkinson s disease: Practical management of medical issues. Parkinsonism and Related Disorders 2008; 14: Calne S, et al. Psychosocial issues in youngonset Parkinson s disease: Current research and challenges. Parkinsonism and Related Disorders 2008; 14:
Parkinson s Disease and Treatment Options for the Younger Adult
The Way CME Should Be Parkinson s Disease and Treatment Options for the Younger Adult David E. Riley, M.D. Chair, Medical Education InMotion April 22, 2016 Case Presentation - 1 A 57-year-old woman had
More informationPharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Assistant Professor of Neurology
+ Pharmacologic Treatment of Parkinson s Disease Nicholas J. Silvestri, M.D. Assistant Professor of Neurology + Overview n Brief review of Parkinson s disease (PD) n Clinical manifestations n Pathophysiology
More informationPharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Associate Professor of Neurology
+ Pharmacologic Treatment of Parkinson s Disease Nicholas J. Silvestri, M.D. Associate Professor of Neurology + Disclosures n NO SIGNIFICANT FINANCIAL, GENERAL, OR OBLIGATION INTERESTS TO REPORT + Learning
More informationparts of the gastrointenstinal tract. At the end of April 2008, it was temporarily withdrawn from the US Market because of problems related to
parts of the gastrointenstinal tract. At the end of April 2008, it was temporarily withdrawn from the US Market because of problems related to crystallization of the drug, which caused unreliable drug
More informationOptimizing Clinical Communication in Parkinson s Disease:
Optimizing Clinical Communication in Parkinson s Disease:,Strategies for improving communication between you and your neurologist PFNCA Symposium March 25, 2017 Pritha Ghosh, MD Assistant Professor of
More informationBest Medical Treatments for Parkinson s disease
Best Medical Treatments for Parkinson s disease Bernadette Schöneburg, M.D. June 20 th, 2015 What is Parkinson s Disease (PD)? Progressive neurologic disorder that results from the loss of specific cells
More informationScott J Sherman MD, PhD The University of Arizona PARKINSON DISEASE
Scott J Sherman MD, PhD The University of Arizona PARKINSON DISEASE LEARNING OBJECTIVES The Course Participant will: 1. Be familiar with the pathogenesis of Parkinson s Disease (PD) 2. Understand clinical
More informationParkinson s Disease Medications: Professionals Edition
Parkinson s Disease Clinic and Research Center University of California, San Francisco 505 Parnassus Ave., Rm. 795-M, Box 0114 San Francisco, CA 94143-0114 (415) 476-9276 http://pdcenter.neurology.ucsf.edu
More informationMedications used to treat Parkinson s disease
Medications used to treat Parkinson s disease Edwin B. George, M.D., Ph.D. Director of Wayne State University Movement Disorder Clinic University Health Center Neurology Clinic University Health The John
More informationMotor Fluctuations Stephen Grill, MD, PHD Parkinson s and Movement Disorders Center of Maryland and Johns Hopkins University
Motor Fluctuations Stephen Grill, MD, PHD Parkinson s and Movement Disorders Center of Maryland and Johns Hopkins University I have no financial interest with any entity producing marketing, re-selling,
More informationParkinson s Disease WHERE HAVE WE BEEN, WHERE ARE WE HEADING? CHARLECE HUGHES D.O.
Parkinson s Disease WHERE HAVE WE BEEN, WHERE ARE WE HEADING? CHARLECE HUGHES D.O. Parkinson s Epidemiology AFFECTS 1% OF POPULATION OVER 65 MEAN AGE OF ONSET 65 MEN:WOMEN 1.5:1 IDIOPATHIC:HEREDITARY 90:10
More informationPARKINSON S MEDICATION
PARKINSON S MEDICATION History 1940 50 s Neurosurgeons operated on basal ganglia. Improved symptoms. 12% mortality 1960 s: Researchers identified low levels of dopamine caused Parkinson s leading to development
More informationTreatment of Parkinson s Disease: Present and Future
Treatment of Parkinson s Disease: Present and Future Karen Blindauer, MD Professor of Neurology Director of Movement Disorders Program Medical College of Wisconsin Neuropathology: Loss of Dopamine- Producing
More informationParkinson s Disease Update. Presented by Joanna O Leary, MD Movement disorder neurologist Providence St. Vincent s
Parkinson s Disease Update Presented by Joanna O Leary, MD Movement disorder neurologist Providence St. Vincent s What is a movement disorder? Neurological disorders that affect ability to move by causing
More informationEvaluation of Parkinson s Patients and Primary Care Providers
Evaluation of Parkinson s Patients and Primary Care Providers 2018 Movement Disorders Half Day Symposium Elise Anderson MD Medical Co-Director, PBSI Movement Disorders 6/28/2018 1 Disclosures GE Speaker,
More informationKey Concepts and Issues in Parkinson s Disease in 2016
Key Concepts and Issues in Parkinson s Disease in 2016 Michael Rezak, M.D., Ph.D. Section Chief, Neurosciences Institute Director, Movement Disorders and Neurodegenerative Diseases Center Northwestern
More informationCardinal Features of Parkinson s. Management of Parkinson s Disease. Drug Induced Parkinson s. Other Parkinson s Symptoms.
Cardinal Features of Parkinson s Management of Parkinson s Disease Kristin S. Meyer, PharmD, CGP, FASHP Assistant Professor of Pharmacy Practice Drake University & Iowa Veterans Home Spring 2009 Tremor
More informationParkinson s Disease Current Treatment Options
Parkinson s Disease Current Treatment Options Daniel Kassicieh, D.O., FAAN Sarasota Neurology, P.A. PD: A Chronic Neurodegenerative Ds. 1 Million in USA Epidemiology 50,000 New Cases per Year Majority
More informationParkinson s Disease. Sirilak yimcharoen
Parkinson s Disease Sirilak yimcharoen EPIDEMIOLOGY ~1% of people over 55 years Age range 35 85 years peak age of onset is in the early 60s ~5% of cases characterized by an earlier age of onset (typically
More informationPARKINSON S DISEASE. Nigrostriatal Dopaminergic Neurons 5/11/16 CARDINAL FEATURES OF PARKINSON S DISEASE. Parkinson s disease
5/11/16 PARKINSON S DISEASE Parkinson s disease Prevalence increases with age (starts 40s60s) Seen in all ethnic groups, M:F about 1.5:1 Second most common neurodegenerative disease Genetics role greater
More information10th Medicine Review Course st July Prakash Kumar
10th Medicine Review Course 2018 21 st July 2018 Drug Therapy for Parkinson's disease Prakash Kumar National Neuroscience Institute Singapore General Hospital Sengkang General Hospital Singhealth Duke-NUS
More informationDrug Therapy of Parkinsonism. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Drug Therapy of Parkinsonism Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Parkinsonism is a progressive neurological disorder of muscle movement, usually
More informationMedication Management & Strategies When the levodopa honeymoon is over
Medication Management & Strategies When the levodopa honeymoon is over Eric J Pappert, MD Parkinson s Disease & Movement Disorders Center Neurology Associates Medication Options in Parkinson s Carbidopa/Levodopa
More informationProgram Highlights. Michael Pourfar, MD Co-Director, Center for Neuromodulation New York University Langone Medical Center New York, New York
Program Highlights David Swope, MD Associate Professor of Neurology Mount Sinai Health System New York, New York Michael Pourfar, MD Co-Director, Center for Neuromodulation New York University Langone
More informationEvaluation and Management of Parkinson s Disease in the Older Patient
Evaluation and Management of Parkinson s Disease in the Older Patient David A. Hinkle, MD, PhD Comprehensive Movement Disorders Clinic Pittsburgh Institute for Neurodegenerative Diseases University of
More informationWHAT DEFINES YOPD? HANDLING UNIQUE CONCERNS REBECCA GILBERT, MD, PHD VICE PRESIDENT, CHIEF SCIENTIFIC OFFICER, APDA MARCH 14, 2019
WHAT DEFINES YOPD? HANDLING UNIQUE CONCERNS REBECCA GILBERT, MD, PHD VICE PRESIDENT, CHIEF SCIENTIFIC OFFICER, APDA MARCH 14, 2019 YOUNG ONSET PARKINSON S DISEASE Definition: Parkinson s disease diagnosed
More informationParkinson s Disease. Prevalence. Mark S. Baron, M.D. Cardinal Features. Clinical Characteristics. Not Just a Movement Disorder
Prevalence Parkinson s Disease Mark S. Baron, M.D. Associate Professor of Neurology Movement Disorders Section VCU School of Medicine Common disorder Approaching 1% by 65 yrs of age, 2% by 80 yrs of age
More informationPD: Key Treatment Considerations
PD: Key Treatment Considerations 2018 Management of Neurologic and Neurosurgical Disorders in Daily Practice Elise Anderson MD Medical Co-Director, PBSI Movement Disorders 11/27/2018 1 Outline Treatment
More informationFaculty. Joseph Friedman, MD
Faculty Claire Henchcliffe, MD, DPhil Associate Professor of Neurology Weill Cornell Medical College Associate Attending Neurologist New York-Presbyterian Hospital Director of the Parkinson s Institute
More informationPrior Authorization with Quantity Limit Program Summary
Gocovri (amantadine) Prior Authorization with Quantity Limit Program Summary This prior authorization applies to Commercial, NetResults A series, SourceRx and Health Insurance Marketplace formularies.
More information9/26/18. Objectives. Disclosures. Parkinson s Disease Update Clinical and Operational Considerations
Parkinson s Disease Update Clinical and Operational Considerations Dana Saffel, PharmD, BCGP, CPh, FASCP President, CEO PharmaCare Strategies, Inc. September 2018 Objectives Describe epidemiology and pathophysiology
More informationCommunicating About OFF Episodes With Your Doctor
Communicating About OFF Episodes With Your Doctor Early in Parkinson s disease (PD), treatment with levodopa and other anti-pd drugs provides continuous benefit. As the disease progresses, however, symptom
More informationParkinson s Disease Update. Colleen Peach, RN, MSN, FNP Movement Disorders Clinic Emory University School of Medicine March 7, 2015
Parkinson s Disease Update Colleen Peach, RN, MSN, FNP Movement Disorders Clinic Emory University School of Medicine March 7, 2015 Parkinson s Disease Progressive, chronic, neurodegenerative disease Slow,
More informationWhat s new for diagnosing and treating Parkinson s Disease?
What s new for diagnosing and treating Parkinson s Disease? Erika Driver-Dunckley, MD Associate Professor of Neurology Program Director Movement Disorders Fellowship Assistant Program Director Neurology
More informationParkinson s Disease Update
Parkinson s Disease Update Elise Anderson MD Providence Center for Parkinson s Disease October 26, 2017 11/6/2017 1 Disclosures GE Speaker, DaTSCAN 11/6/2017 2 Outline PD diagnosis Motor and nonmotor symptoms
More informationHistory Parkinson`s disease. Parkinson's disease was first formally described in 1817 by a London physician named James Parkinson
Parkinsonismm History Parkinson`s disease Parkinson's disease was first formally described in 1817 by a London physician named James Parkinson Definition : Parkinsonism: Parkinsonism is a progressive neurological
More informationTreatment of Parkinson s Disease and of Spasticity. Satpal Singh Pharmacology and Toxicology 3223 JSMBS
Treatment of Parkinson s Disease and of Spasticity Satpal Singh Pharmacology and Toxicology 3223 JSMBS singhs@buffalo.edu 716-829-2453 1 Disclosures NO SIGNIFICANT FINANCIAL, GENERAL, OR OBLIGATION INTERESTS
More informationWelcome and Introductions
Parkinson s Disease Spotlight on Treatment Advances Tuesday, January 26, 2016 Welcome and Introductions Stephanie Paul Vice President Development and Marketing American Parkinson Disease Association 1
More information8/28/2017. Behind the Scenes of Parkinson s Disease
BEHIND THE SCENCES IN Parkinson s Disease Behind the Scenes of Parkinson s Disease Anna Marie Wellins DNP, ANP C Objectives Describe prevalence of Parkinson's disease (PD) Describe the hallmark pathologic
More informationThe symptoms of the Parkinson s disease may vary from person to person. The symptoms might include the following:
1 PARKINSON S DISEASE Parkinson's disease is a long term disease related to the central nervous system that mainly affects the motor system, resulting in the loss of dopamine, which helps in producing
More informationOverview. Overview. Parkinson s disease. Secondary Parkinsonism. Parkinsonism: Motor symptoms associated with impairment in basal ganglia circuits
Overview Overview Parkinsonism: Motor symptoms associated with impairment in basal ganglia circuits The differential diagnosis of Parkinson s disease Primary vs. Secondary Parkinsonism Proteinopathies:
More informationUnderstanding Parkinson s Disease Important information for you and your loved ones
Patient Education Understanding Parkinson s Disease Important information for you and your loved ones This handout explains the signs, symptoms, and possible treatments of Parkinson s disease. Parkinson
More informationObjectives. Emerging Treatments in Parkinson s s Disease. Pathology. As Parkinson s progresses it eventually affects large portions of the brain.
Objectives Emerging Treatments in Parkinson s s Disease 1) Describe recent developments in the therapies for Parkinson s Disease Jeff Kraakevik MD Assistant Professor OHSU/Portland VAMC Parkinson s Center
More informationPharmacy Coverage Guidelines are subject to change as new information becomes available.
ZELAPAR (selegiline hydrochloride) orally disintegrating tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific
More informationPARKINS ON CENTER. Parkinson s Disease: Diagnosis and Management. Learning Objectives: Recognition of PD OHSU. Disclosure Information
OHSU PARKINS ON CENTER Parkinson s Disease: Diagnosis and Management for Every MD Disclosure Information Grants/Research Support: National Parkinson Foundation, NIH, Michael J. Fox Foundation Consultant:
More informationARE YOUR LEVODOPA PILLS WORKING LIKE THEY USED TO?
ARE YOUR LEVODOPA PILLS WORKING LIKE THEY USED TO? You may have noticed a change... Levodopa is a common treatment for Parkinson s, and doctors have relied on it for decades. Over time as Parkinson s progresses,
More informationIssues for Patient Discussion
onmotor complications radykinesia Screening Tools asked PD micrographia eurodegeneration Designed for Use by Family Practitioners remor on-off opamine agonists tiffness depression ostural instability wearing
More informationParkinson Disease. Lorraine Kalia, MD, PhD, FRCPC. Presented by: Ontario s Geriatric Steering Committee
Parkinson Disease Lorraine Kalia, MD, PhD, FRCPC Key Learnings Parkinson Disease (L. Kalia) Key Learnings Parkinson disease is the most common but not the only cause of parkinsonism Parkinson disease is
More informationPARKINSON S PRIMER. Dr. Kathryn Giles MD, MSc, FRCPC Cambridge, Ontario, Canada
PARKINSON S PRIMER Dr. Kathryn Giles MD, MSc, FRCPC Cambridge, Ontario, Canada COPYRIGHT 2017 BY SEA COURSES INC. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted
More informationParkinson s Disease. Patients will ask you. 8/14/2015. Objectives
Parkinson s Disease Jean Van Kingsley MS, FNP-BC Objectives Describe the pathophysiolgy of PD. Review clinical charachteristics of PD. Identify management strategies, to maximize functional status. Recognize
More informationAlison Charleston 1 st September 2016
Alison Charleston 1 st September 2016 Clinical features of Parkinson s disease Differential diagnosis Management of the motor features Non-motor and neuropsychiatric aspects 100-200 per 100,000 prevalence
More informationWhat is Parkinson s Disease?
2018 Update in Parkinson s Disease: Treatments and Future Plans Arita McCoy, MSN, CRNP Johns Hopkins Parkinson s Disease and Movement Disorder Center A National Parkinson Foundation Center of Excellence
More informationEnhanced Primary Care Pathway: Parkinson s Disease
Enhanced Primary Care Pathway: Parkinson s Disease 1. Focused summary of PD relevant to primary care Parkinson s Disease (PD) and Essential tremor (ET) are two of the most common movement disorders encountered
More informationDrugs for Parkinson s Disease
This Clinical Resource gives subscribers additional insight related to the Recommendations published in July 2017 ~ Resource #330705 Drugs for Parkinson s Disease Parkinson s disease is characterized by
More informationNon-Motor Symptoms of Parkinson s Disease
Non-Motor Symptoms of Parkinson s Disease Samantha Holden, MD University of Colorado Movement Disorders MOTOR SYMPTOMS Rigidity Bradykinesia Tremor Gait Imbalance NON-MOTOR SYMPTOMS Dementia Urinary frequency
More informationParkinson s Disease. Gillian Sare
Parkinson s Disease Gillian Sare Outline Reminder about PD Parkinson s disease in the inpatient Surgical patients with PD Patients who cannot swallow End of life care Parkinson s disease PD is the second
More informationIII./3.1. Movement disorders with akinetic rigid symptoms
III./3.1. Movement disorders with akinetic rigid symptoms III./3.1.1. Parkinson s disease Parkinson s disease (PD) is the second most common neurodegenerative disorder worldwide after Alzheimer s disease.
More informationParkinson s disease Therapeutic strategies. Surat Tanprawate, MD Division of Neurology University of Chiang Mai
Parkinson s disease Therapeutic strategies Surat Tanprawate, MD Division of Neurology University of Chiang Mai 1 Scope Modality of treatment Pathophysiology of PD and dopamine metabolism Drugs Are there
More informationWelcome and Introductions
Parkinson s Disease Spotlight on Addressing Motor and Non-Motor Symptoms The Changing Landscape Wednesday, March 8, 2017 Welcome and Introductions Stephanie Paul Vice President Development and Marketing
More informationParkinson s Disease: initial diagnosis, initial treatment & non-motor features. J. Timothy Greenamyre, MD, PhD
Parkinson s Disease: initial diagnosis, initial treatment & non-motor features J. Timothy Greenamyre, MD, PhD Involuntary tremulous motion, with lessened muscular power, in parts not in action and even
More informationMovement Disorders: A Brief Overview
Movement Disorders: A Brief Overview Albert Hung, MD, PhD Massachusetts General Hospital Harvard Medical School August 17, 2006 Cardinal Features of Parkinsonism Tremor Rigidity Bradykinesia Postural imbalance
More informationCommonly encountered medications and their side effects - what the generalist needs to know
Commonly encountered medications and their side effects - what the generalist needs to know Jeremy Cosgrove Consultant Neurologist Leeds Teaching Hospitals NHS Trust Outline: Parkinson s medications and
More informationDate of Referral: Enhanced Primary Care Pathway: Parkinson s Disease
Specialist LINK Linking Physicians CALGARY AND AREA Patient Name: Date of Birth: Calgary RHRN: PHN / ULI: Date of Referral: Referring MD: Fax: Today s Date: CONFIRMATION: TRIAGE CATEGORY: REFERRAL STATUS:
More informationMotor Fluctuations in Parkinson s Disease
Motor Fluctuations in Parkinson s Disease Saeed Bohlega, MD, FRCPC Senior Distinguished Consultant Department of Neurosciences King Faisal Specialist Hospital & Research Centre Outline Type of fluctuations
More informationThe Fresco Institute for Parkinson's and Movement Disorders
The Fresco Institute for Parkinson's and Movement Disorders Follow Up Patient Questionnaire Name: Date: Accompanied by: Do you smoke? CURRENT PAST NEVER Which neurological symptom bothers you most right
More information2/20/18. History of Parkinson s. What is happening in the brain? DOPAMINE! Epidemiology. Parkinson s Disease. It s much more than tremor
Parkinson s Disease History of Parkinson s It s much more than tremor Laura Dixon, DNP, MPA, APRN, FNP-BC University of Louisville Department of Neurology Movement Disorders Division Parkinson s Disease
More informationPD ExpertBriefings: Parkinson s Medications: Today and Tomorrow Led By: Cynthia L. Comella, M.D., F.A.A.N.
PD ExpertBriefings: Parkinson s Medications: Today and Tomorrow Led By: Cynthia L. Comella, M.D., F.A.A.N. To hear the session live on: Tuesday, April 17, 2012 at 1:00 PM ET. DIAL: 1 (888) 272-8710 and
More informationMEDICATION GUIDE DUOPA (Do-oh-pa) (carbidopa and levodopa) enteral suspension
MEDICATION GUIDE DUOPA (Do-oh-pa) (carbidopa and levodopa) enteral suspension Read this Medication Guide before you start using DUOPA and each time you get a refill. There may be new information. This
More information2-The age at onset of PD is variable, usually between 50 and 80 years, with a mean onset of 55 years (1).
Parkinson Disease 1-Parkinson disease (PD) is a chronic, progressive movement disorder resulting from loss of dopamine from the nigrostriatal tracts in the brain, and is characterized by rigidity, bradykinesia,
More informationDrugs Affecting the Central Nervous System
Asst Prof Inam S Arif isamalhaj@yahoo.com Drugs Affecting the Central Nervous System Ass Efferent neurons in ANS Neurodegenerative Diseases Parkinson s Disease Multiple Sclerosis Alzheimer s Disease
More informationParkinsons Disease update. Sindhu R Srivatsal MD MPH Virginia Mason Medical Center
Parkinsons Disease update Sindhu R Srivatsal MD MPH Virginia Mason Medical Center PARKINSONISM Vs PARKINSON S Parkinsonism Bradykinesia: slowness of movements (essential feature) PLUS one of Tremor: resting
More informationRe-Submission. Scottish Medicines Consortium. rasagiline 1mg tablet (Azilect ) (No. 255/06) Lundbeck Ltd / Teva Pharmaceuticals Ltd.
Scottish Medicines Consortium Re-Submission rasagiline 1mg tablet (Azilect ) (No. 255/06) Lundbeck Ltd / Teva Pharmaceuticals Ltd 10 November 2006 The Scottish Medicines Consortium (SMC) has completed
More informationWhat is the best medical therapy for early Parkinson's disease? Medications Commonly Used for Parkinson's Disease
FPIN's Clinical Inquiries Treatment of Early Parkinson's Disease Clinical Question What is the best medical therapy for early Parkinson's disease? Evidence-Based Answer Treatment of early Parkinson's disease
More informationTHE ART OF MEDICATION MANAGEMENT IN PARKINSON S DISEASE
THE ART OF MEDICATION MANAGEMENT IN PARKINSON S DISEASE J O N AT H A N S Q U I R E S, M D, F R C P C C L I N I C A L I N S T R U C T O R, UBC F AC U L T Y O F M E D I C I N E P AC I F I C P AR K I N S
More informationDrugs used in Parkinsonism
Drugs used in Parkinsonism قادة فريق علم األدوية : لي التميمي & عبدالرحمن ذكري الشكر موصول ألعضاء الفريق املتميزين : جومانة القحطاني ندى الصومالي روان سعد القحطاني pharma436@outlook.com @pharma436 Your
More informationHeadway Victoria Epilepsy and Parkinson s Centre
Headway Victoria Epilepsy and Parkinson s Centre Parkinson s Overview and Medication Shannon Oatway Community Education/ Awareness Coordinator What is Parkinson s Disease? The basics It is a chronic and
More informationAnticholinergics. COMT* Inhibitors. Dopaminergic Agents. Dopamine Agonists. Combination Product
Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-945-5220 Fax 503-947-1119 Class Update: Parkinson s Drugs Month/Year of Review:
More information05-Nov-15. Impact of Parkinson s Disease in Australia. The Nature of Parkinson s disease 21st Century
Peter Silburn Professor Clinical Neuroscience University of Queensland Queensland Brain Institute Neurosciences Queensland Impact of in Australia Second most common neurodegenerative disorder Up to 64,000
More informationParkinson s disease. Information for patients and carers. The Leeds Teaching Hospitals NHS Trust
n The Leeds Teaching Hospitals NHS Trust Parkinson s disease Information for patients and carers in partnership with Leeds Community Healthcare NHS Trust The symptoms of Parkinson s appear when the levels
More informationThe Role of Pharmacists in Treating & Managing Parkinson s Disease Author: Mary Jo Carden, RPh, JD Principal, Carden Associates
The Role of Pharmacists in Treating & Managing Parkinson s Disease Author: Mary Jo Carden, RPh, JD Principal, Carden Associates Editor: Marsha K. Millonig, MBA, RPh President/CEO Catalyst Enterprises,
More informationFaculty Information 2/15/2013
Timothy Reilly, PharmD, BCPS, CGP, FASCP Clinical Assistant Professor Ernest Mario School of Pharmacy Rutgers, The State University of New Jersey tjreilly@pharmacy.rutgers.edu Faculty Information Presenter:
More informationDr Barry Snow. Neurologist Auckland District Health Board
Dr Barry Snow Neurologist Auckland District Health Board Dystonia and Parkinson s disease Barry Snow Gowers 1888: Tetanoid chorea Dystonia a movement disorder characterized by sustained or intermittent
More informationDrug Management of Parkinsonism. By Prof. Mohammad Saleh M. Hassan PhD. (Pharma); MSc. (Ped.); MHPE (Ed.)
Drug Management of Parkinsonism By Prof. Mohammad Saleh M. Hassan PhD. (Pharma); MSc. (Ped.); MHPE (Ed.) Drug management of Parkinsonism Levodopa Ergot derivatives noamine Oxidaes Inhibitors Catechol-Omethyl
More information475 GERIATRIC PSYCHOPHARMACOLOGY (p.1)
475 GERIATRIC PSYCHOPHARMACOLOGY (p.1) I. General Information? Use lower doses? Start low and go slow? Expect prolonged elimination ½ lives? Expect sedative-hypnotics to be dementing, to impair cognitive
More informationPresented by Meagan Koepnick, Josh McDonald, Abby Narayan, Jared Szabo Mentored by Dr. Doorn
Presented by Meagan Koepnick, Josh McDonald, Abby Narayan, Jared Szabo Mentored by Dr. Doorn Objectives What agents do we currently have available and what do we ideally need? What biomarkers exist for
More informationParkinson's Disease and how you can make a difference with medication
Parkinson's Disease and how you can make a difference with medication Alyson Franks Parkinson's and Movement Disorder Nurse Specialist Royal Hallamshire Hospital No treatment all Complementary Therapy
More informationM. Carranza M. R. Snyder J. Davenport Shaw T. A. Zesiewicz. Parkinson s Disease. A Guide to Medical Treatment
M. Carranza M. R. Snyder J. Davenport Shaw T. A. Zesiewicz Parkinson s Disease A Guide to Medical Treatment SEEd srl. All rights reserved Piazza Carlo Emanuele II, 19 10123 Torino, Italy Tel. 011.566.02.58
More informationPL CE LIVE July 2015 Forum
July 2015 PL CE LIVE Rachel Maynard, PharmD Associate Editor Pharmacist s Letter/Pharmacy Technician s Letter CE Information Pharmacist's Letter / Therapeutic Research Center is accredited by the Accreditation
More informationAdvanced Therapies for Motor Symptoms in PD. Matthew Boyce MD
Advanced Therapies for Motor Symptoms in PD Matthew Boyce MD Medtronic Education Teva Speakers Bureau Acadia Speakers Bureau Disclosures Discuss issues in advanced PD Adjunct therapies to levo-dopa Newer
More informationPharmacy Coverage Guidelines are subject to change as new information becomes available.
ZELAPAR (selegiline hydrochloride) orally disintegrating tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific
More informationMultiple choice questions: ANSWERS
Multiple choice questions: ANSWERS Chapter 1. Redefining Parkinson s disease 1. Common non-motor features that precede the motor findings in Parkinson s disease (PD) include all of the following except?
More informationIntroductory Clinical Pharmacology Chapter 32 Antiparkinsonism Drugs
Introductory Clinical Pharmacology Chapter 32 Antiparkinsonism Drugs Dopaminergic Drugs: Actions Symptoms of parkinsonism are caused by depletion of dopamine in CNS Amantadine: makes more of dopamine available
More informationParkinson's Disease KP Update
Parkinson's Disease KP Update Andrew Imbus, PA-C Neurology, Movement Disorders Kaiser Permanente, Los Angeles Medical Center No disclosures "I often say now I don't have any choice whether or not I have
More informationTRANSPARENCY COMMITTEE OPINION. 18 March 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 March 2009 REQUIP LP 2 mg extended-release tablet Box of 21 tablets (CIP: 379 214-8) Box of 28 tablets (CIP: 379
More informationAppendix 2: Admissions checklists for people with Parkinson s
Appendix 2: Admissions checklists for people with Parkinson s This document is intended to form the basis of a locally developed tool and so it has been built to be amended with relevant local information,
More informationParkinson s Disease Initial Clinical and Diagnostic Evaluation. J. Timothy Greenamyre, MD, PhD
Parkinson s Disease Initial Clinical and Diagnostic Evaluation J. Timothy Greenamyre, MD, PhD Involuntary tremulous motion, with lessened muscular power, in parts not in action and even when supported
More informationLiterature Scan: Anti-Parkinson s Agents
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationLet s Look at Parkinson s (PD) Sheena Morgan Parkinson s Disease Nurse Specialist Isle of Wight NHS Trust November 2016
Let s Look at Parkinson s (PD) Sheena Morgan Parkinson s Disease Nurse Specialist Isle of Wight NHS Trust November 2016 What is Parkinson s? Parkinson's is a progressive neurological condition. People
More informationChapter 20. Media Directory. Amyotrophic Lateral Sclerosis. Alzheimer s Disease. Huntington s Chorea. Multiple Sclerosis
Chapter 20 Drugs for Degenerative Diseases of the Nervous System Slide 18 Media Directory Levadopa Animation Upper Saddle River, New Jersey 07458 All rights reserved. Alzheimer s Disease Amyotrophic Lateral
More information